12(S)-Hydroperoxy-eicosatetraenoic acid increases arachidonic acid availability in collagen-primed platelets.
Lipid hydroperoxides have been reported to regulate cell function and eicosanoid formation. The aim of the present study was to determine the effect of 12(S)-hydroperoxy-eicosatetraenoic acid [12(S)-HPETE], the platelet 12-lipoxygenase-derived hydroperoxide of arachidonic acid (AA), on the availability of nonesterified AA, which represents a rate-limiting step in the biosynthesis of eicosanoids. The coincubation of human platelets with concentrations of 12(S)-HPETE below 50 nM and subthreshold concentrations (STC) of collagen (less than 0.24 microg/ml) significantly enhanced platelet aggregation and the formation of thromboxane B(2), the stable catabolite of the potent aggregating agent thromboxane A(2). In addition, the nonesterified endogenous AA concentration increased by 3-fold. Arachidonoyl-containing molecular species concentrations of 1,2-diacyl-glycero-3-phosphocholine, 1-alkyl-2-acyl-glycero-3-phosphocholine, and 1-alkenyl-2-acyl-glycero-3-phosphoethanolamine decreased specifically in response to 12(S)-HPETE, whereas no significant changes were observed within 1,2-diacyl-glycero-3-phosphoethanolamine and 1,2-diacyl-glycero-3-phosphoinositol molecular species. The 12(S)-HPETE-induced increase in nonesterified AA was fully prevented by arachidonoyl trifluoromethyl ketone, an inhibitor of cytosolic phospholipase A(2) (cPLA(2)), and cPLA(2) was translocated to membranes and phosphorylated in platelets incubated with 12(S)-HPETE. In conclusion, these results indicate that nanomolar concentrations of 12(S)-HPETE could play a significant role in controlling the level of endogenous AA and the formation of thromboxane, thereby potentiating platelet function.
Calzada
C
C
INSERM U 352, Biochimie et Pharmacologie, INSA-Lyon, 69621 Villeurbanne, France. Catherine.Calzada@insa-lyon.fr
Véricel
E
E
Mitel
B
B
Coulon
L
L
Lagarde
M
M
D016718:Arachidonic Acid / Q000097:blood*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism*; D003094:Collagen / Q000008:administration & dosage / Q000494:pharmacology*; D020404:Glycerophospholipids / Q000097:blood; D005997:Glycerylphosphorylcholine / Q000097:blood; D006801:Humans; D015289:Leukotrienes / Q000008:administration & dosage / Q000494:pharmacology*; D010714:Phosphatidylethanolamines / Q000097:blood; D010716:Phosphatidylinositols / Q000097:blood; D010741:Phospholipases A / Q000378:metabolism; D010766:Phosphorylation; D010974:Platelet Aggregation / Q000187:drug effects; D013929:Thromboxane B2 / Q000097:blood
D020404:Glycerophospholipids; D015289:Leukotrienes; D010714:Phosphatidylethanolamines; D010716:Phosphatidylinositols; D016718:Arachidonic Acid; D013929:Thromboxane B2; D005997:Glycerylphosphorylcholine; C021201:12-HPETE; D003094:Collagen; D010741:Phospholipases A